| 1 |
Mukherji D,Pezaro CJ,Shamseddine A, et al. New treatment developments applied to elderly patients with advanced prostate cancer[J]. Cancer Treat Rev, 2013,39(6):578-583.
|
| 2 |
Loriot Y,Zoubeidi A,G. ME. Targeted therapies in metastatic castration-resistant prostate cancer:beyond the androgen receptor[J]. Urol Clin North Am, 2012,39(4):517-531.
|
| 3 |
Wadosky KM,Koochekpour S. Molecular mechanisms underlying resistance to androgendeprivation therapy in prostate cancer[J]. Oncotarget, 2016,7(39):64447-64470.
|
| 4 |
Hoang DT,Iczkowski KA,Kilari D, et al. Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles[J]. Oncotarget, 2017,8(2):3724-3745.
|
| 5 |
Ringel I,Horwitz SB. Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol[J]. J Natl Cancer Inst, 1991,83(4):288-291.
|
| 6 |
Handy CE,Antonarakis ES. Sequencing treatment for castration-resistant prostate cancer[J]. Curr Treat Options Oncol, 2016,17(12):64.
|
| 7 |
Oh WK,Kantoff PW. Docetaxel(Taxotere)-based chemotherapy for hormone-refractory and locally advanced prostate cancer[J]. Semin Oncol, 1999,26(5Suppl17):49-54.
|
| 8 |
Yoo S,Choi SY,You D, et al.New drugs in prostate cancer[J]. Prostate Int, 2016,4(2):37-42.
|
| 9 |
Sun Y,Zou Q,Sun Z, et al. Abiraterone acetate for metastatic castration-resistant prostate cancer after docetaxel failure: A randomized, double-blind, placebo-controlled phase 3 bridging study[J]. Int J Urol, 2016,23(5):404-411.
|
| 10 |
Roos WP,Krumm A. The multifaceted influence of histone deacetylases on DNA damage signalling and DNA repair[J]. Nucleic Acids Res, 2016,44(21):10017-10030.
|
| 11 |
De Souza C,Chatterji BP. HDAC Inhibitors as novel anti-cancer therapeutics[J]. Recent Pat Anticancer Drug Discov, 2015,10(2):145-162.
|
| 12 |
Marks PA,Richon VM,Breslow R, et al. Histone deacetylase inhibitors as new cancer drugs[J]. Curr Opin Oncol, 2001,13(6):477-483.
|
| 13 |
Greer CB,Tanaka Y,Kim YJ, et al. Histone deacetylases positively regulate transcription through the elongation machinery[J]. Cell Rep, 2015,13(7):1444-1455.
|
| 14 |
Kim YJ,Greer CB,Cecchini KR, et al. HDAC inhibitors induce transcriptional repression of high copy number genes in breast cancer through elongation blockade[J]. Oncogene, 2013,32(23):2828-2835.
|
| 15 |
Yoshida M,Kijima M,Akita M, et al. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A[J]. J Biol Chem, 1990,265(28):17174-17179.
|
| 16 |
Zhang Q,Sun M,Zhou S, et al. Class I HDAC inhibitor mocetinostat induces apoptosis by activation of miR-31 expression and suppression of E2F6[J]. Cell Death Discov, 2016,2:16036.
|
| 17 |
Hwang JJ,Kim YS,Kim MJ, et al. A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL[J]. Invest New Drugs, 2012,30(4):1434-1442.
|
| 18 |
Hassig CA,Symons KT,Guo X, et al. KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo[J]. Mol Cancer Ther, 2008,7(5):1054-1065.
|
| 19 |
Li X,Kaplun A,Lonardo F, et al. HDAC1 inhibition by maspin abrogates epigenetic silencing of glutathione S-transferase pi in prostate carcinoma cells[J]. Mol Cancer Res, 2011,9(6):733-745.
|
| 20 |
Bai P. Biology of poly(ADP-Ribose) polymerases: The factotums of cell maintenance[J]. Mol Cell, 2015,58(6):947-958.
|
| 21 |
Sharma A,Singh K,Almasan A. Histone H2AX phosphorylation: a marker for DNA damage[J]. Methods Mol Biol, 2012,920:613-626.
|
| 22 |
Wang B,Yong H,Zhu H, et al. Abnormal amphiregulin expression correlates with gastric cancer prognosis[J]. Oncotarget, 2016,7(47): 76684-76692.
|
| 23 |
Li X,Yin S,Meng Y, et al. Endogenous inhibition of histone deacetylase 1 by tumor-suppressive maspin[J]. Cancer Res, 2006, 66(18):9323-9329.
|
| 24 |
Yin S,Li X,Meng Y, et al. Tumor-suppressive maspin regulates cell response to oxidative stress by direct interaction with glutathione S-transferase[J]. J Biol Chem, 2005,280(41):34985-34996.
|
| 25 |
Zou Z,Anisowicz A,Hendrix MJ, et al. Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells[J]. Science, 1994,263(5146):526-529.
|
| 26 |
Thurn KT,Thomas S,Moore A, et al. Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer[J]. Future Oncol, 2011,7(2):263-283.
|
| 27 |
Zhang QC,Jiang SJ,Zhang S, et al. Histone deacetylase inhibitor trichostatin A enhances anti-tumor effects of docetaxel or erlotinib in A549 cell line[J]. Asian Pac J Cancer Prev, 2012,13(7):3471-3476.
|
| 28 |
Chikamatsu K,Ishii H,Murata T, et al. Alteration of cancer stem cell-like phenotype by histone deacetylase inhibitors in squamous cell carcinoma of the head and neck[J]. Cancer Sci, 2013,104(11):1468-1475.
|
| 29 |
Biernacka KM,Uzoh CC,Zeng L, et al. Hyperglycaemia-induced chemoresistance of prostate cancer cells due to IGFBP2[J]. Endocr Relat Cancer, 2013,20(5):741-751.
|
| 30 |
Imesch P,Dedes KJ,Furlato M, et al. MLH1 protects from resistance acquisition by the histone deacetylase inhibitor trichostatin A in colon tumor cells[J]. Int J Oncol, 2009,35(3):631-640.
|
| 31 |
Scholpa NE,Kolli RT,Moore M, et al. Nephrotoxicity of epigenetic inhibitors used for the treatment of cancer[J]. Chem Biol Interact, 2016,258:21-29.
|